Brokerages forecast that Strongbridge Biopharma PLC (NASDAQ:SBBP) will report sales of $1.76 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Strongbridge Biopharma PLC’s earnings. The lowest sales estimate is $1.11 million and the highest is $2.96 million. The firm is expected to report its next quarterly earnings results on Friday, December 22nd.

On average, analysts expect that Strongbridge Biopharma PLC will report full year sales of $1.76 million for the current year, with estimates ranging from $3.18 million to $8.11 million. For the next fiscal year, analysts forecast that the business will report sales of $14.29 million per share, with estimates ranging from $9.39 million to $21.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Strongbridge Biopharma PLC.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.84 million.

A number of equities research analysts have weighed in on SBBP shares. HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma PLC in a report on Wednesday, May 17th. Zacks Investment Research raised shares of Strongbridge Biopharma PLC from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Wednesday, July 19th. ValuEngine raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Finally, Oppenheimer Holdings, Inc. started coverage on shares of Strongbridge Biopharma PLC in a report on Thursday. They set an “outperform” rating and a $12.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Strongbridge Biopharma PLC currently has a consensus rating of “Buy” and an average target price of $11.94.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/brokerages-anticipate-strongbridge-biopharma-plc-nasdaqsbbp-will-announce-quarterly-sales-of-1-76-million/1479010.html.

Shares of Strongbridge Biopharma PLC (SBBP) traded up 6.82% during trading on Friday, reaching $7.05. 35,393 shares of the company traded hands. The firm’s market capitalization is $249.11 million. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85. The company has a 50 day moving average price of $6.86 and a 200 day moving average price of $4.63.

Several hedge funds and other institutional investors have recently modified their holdings of SBBP. Northern Trust Corp purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter worth about $1,462,000. Broadfin Capital LLC increased its position in shares of Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock worth $14,163,000 after buying an additional 87,125 shares during the period. Vanguard Group Inc. purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter worth about $474,000. TIAA CREF Investment Management LLC purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter worth about $449,000. Finally, Citigroup Inc. purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter worth about $338,000.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.